Because the price of insulin and insulin analogs has increased over the past two decades, newer insulin options are often unavailable to many type 2 diabetes mellitus (T2DM) patients that are uninsured or underinsured. When insulin access is a barrier for T2DM patients, a basal insulin with the lowest acquisition cost is advised. In this scenario, human regular or NPH insulins can be used—as they are associated with lower costs—yet because they are not commonly prescribed, clinicians frequently lack the training on how to use these insulin agents. This workshop will review how a clinician can initiate, maintain, and intensify insulin therapy when cost and access to the newer analogs is a barrier. Lecturers will review practical strategies, including how human and NPH insulins differ from insulin analogs, in addition to best practices for optimizing the actions of these insulins (timing of pre-meal injection, strategic snacking, injection site selection) and minimizing the risk of hypoglycemia.